Friday, 16 October 2026European Markets

Energy Markets

4 articles

2.5 Bcf/d Permian pipeline to boost US Gulf Coast LNG exports by 2029

2.5 Bcf/d Permian pipeline to boost US Gulf Coast LNG exports by 2029

MPLX's Blackcomb Pipeline will add 2.5 billion cubic feet per day of Permian gas to Gulf Coast LNG terminals by end-2028. The connection could increase US LNG available for European buyers as the EU seeks alternatives to pipeline gas imports.

ViaNews Editorial Team (Europe)•
European Natural Gas Prices Surge as Commodities Rally Amid Supply Risks

European Natural Gas Prices Surge as Commodities Rally Amid Supply Risks

European natural gas prices are surging as part of a broader commodities rally driven by macro uncertainty and geopolitical supply concerns. Gold futures hit record highs at $4,200/oz while investors rotate into hard assets amid expectations for Federal Reserve rate cuts. The flight-to-safety movement comes as tech indices end winning streaks and supply risk concerns intensify across energy markets.

ViaNews Editorial Team (Europe)•
European Natural Gas Prices Spike as UK Political Turmoil Compounds Energy Market Volatility

European Natural Gas Prices Spike as UK Political Turmoil Compounds Energy Market Volatility

European natural gas prices surged in late November 2026 amid UK political instability and broader commodity market turbulence. The energy price spike coincided with a flight to safe-haven assets, driving gold futures to record $4,200/oz while Bitcoin dropped 19% for the month. Continental energy markets face mounting uncertainty as macro pressures amplify supply concerns.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com